Palatin Technologies, Inc. — Form 10-Q Summary
Business context and reporting period
This unaudited filing covers the three months ended September 30, 2020, Palatin’s first quarter of fiscal 2021. Palatin is a development-stage biopharmaceutical company with FDA-approved Vyleesi for premenopausal women with HSDD and other preclinical and clinical programs.
Effective July 24, 2020, Palatin and AMAG terminated their North American Vyleesi license. Palatin regained development and commercialization rights and began taking responsibility for U.S. marketing, distribution, and manufacturing. Vyleesi is also licensed to partners in China and South Korea.
Financial results and liquidity
| Metric | Three months ended September 30, 2020 | Prior-year period or comparison |
|---|---|---|
| Revenue | $(288,560), all product revenue net of allowances | $97,379 in license and contract revenue in 2019 |
| Net loss | $3,940,776; $0.02 per share | $4,500,949; $0.02 per share in 2019 |
| Research and development | $2,923,851 | $3,127,489 in 2019 |
| Selling, general and administrative | $2,331,606 | $1,832,442 in 2019 |
| Operating cash flow | $3,812,951 provided | $54,837,308 provided in 2019 |
| Cash and cash equivalents | $86,587,455 at September 30 | $82,852,270 at June 30, 2020 |
2020 product revenue comprised $809,100 in gross sales less $1,097,660 in allowances and accruals. The resulting negative net revenue reflects the accounting for product sales and related allowances; the filing does not provide a meaningful gross margin. A $1,623,795 gain from the AMAG license termination reduced operating expenses. Investment income fell to $12,135 from $370,654 in 2019, which management attributed to lower interest rates.
At September 30, current assets were $99.8 million and current liabilities were $12.7 million, implying working capital of approximately $87.1 million. Total liabilities were $24.2 million and stockholders’ equity was $77.0 million. The filing reports no outstanding notes payable; the prior venture loan had matured in 2019. Operating cash flow included a $10.4 million reconciliation adjustment related to cash received in excess of the termination-agreement gain. Cash provided by operations was substantially below the prior-year period, which included timing of AMAG-related receipts.
Material changes and unusual items
- AMAG paid Palatin $12 million at termination; a further $4.3 million is due March 31, 2021 and is recorded as a receivable.
- Palatin assumed Vyleesi inventory and manufacturing obligations, including inventory with a stated fair value of $5.8 million. It recorded estimated losses of $18.194 million for inventory purchase commitments and an additional $2.3 million production-run obligation.
- Total manufacturing and inventory purchase commitments were $18.667 million, including $8.048 million due within one year. The company recorded $7.575 million in other current liabilities and $10.619 million in other long-term liabilities for estimated losses on firm commitments.
- Palatin terminated its prior Catalent manufacturing agreement for a €6 million payment, paid in October 2020 and accrued in the quarter’s estimated commitment losses, and entered a replacement agreement with reduced minimum annual purchase requirements.
- Common shares outstanding were 229,855,417 at quarter-end; 229,901,307 were outstanding as of November 13, 2020.
Outlook, risks, and contingencies
Management said existing cash and cash equivalents were expected to fund current planned operations through at least December 2021. Palatin expects substantial spending on U.S. Vyleesi marketing and distribution and on its development programs, and says additional funding will be needed for required clinical trials and subsequent regulatory submissions. Sustained profitability is uncertain.
Key risks include Vyleesi market acceptance and commercialization, manufacturing and inventory commitments, the need for additional financing, clinical and regulatory uncertainty, and potential COVID-19-related disruption to trials, suppliers, operations, and capital access. COVID-19 could also delay regulatory approvals and royalties from licensees. Vyleesi carries label warnings and contraindications, including uncontrolled hypertension or known cardiovascular disease. The company reported no material changes to the risk factors in its prior Form 10-K, no current legal proceedings, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether Vyleesi sales and realized net revenue improve after Palatin assumed U.S. commercialization, and how sales allowances develop.
- Whether the $4.3 million AMAG payment is received as scheduled and whether any other transition-related amounts remain outstanding.
- How Palatin manages the $18.667 million of supply commitments and the inventory and purchase-commitment loss estimates as demand forecasts change.
- Whether cash use, operating costs, and financing needs remain consistent with management’s stated runway through at least December 2021.
- Progress and timing of Vyleesi post-marketing studies, other clinical programs, and regulatory or commercial activity by the China and South Korea licensees.